Allogene Therapeutics provided an early view of its off-the-shelf CAR T-cell program, reporting MRD negativity in lymphoma patients at a higher rate than observation in an ongoing Phase 3 setting. In an interim futility analysis, 58% of treated patients achieved MRD negativity at day 45 versus 16.7% in the placebo/observation arm. The results relate to cemacabtagene ansegedleucel (cema-cel), an allogeneic (donor-derived) CAR T intended to delay relapse earlier in the disease course after standard R-CHOP. Allogene also cited published literature suggesting that MRD clearance differences of roughly 25–30 percentage points can translate to clinically meaningful benefit. Allogene noted that severe immune or neurological adverse events were limited in the interim data, with the company continuing to enroll and planning larger results in 2027 to evaluate durability and relapse outcomes.